HB 4423 requires the Oklahoma Health Care Authority to verify the immigration status of all Medicaid applicants using the federal SAVE system (or its successor) before approving benefits. It specifically mandates that the Authority notify U.S. Immigration and Customs Enforcement (ICE) if an applicant's status cannot be verified as lawful. This applies to all applicants, including adults applying for child-only Medicaid benefits on behalf of a child. The bill takes effect October 1, 2026, and does not change Medicaid eligibility criteria but adds a verification step for immigration status.
SB 1425 repeals three existing Oklahoma statutes related to health care workforce programs: 70 O.S. 2021 §2640 (Oklahoma Health Care Workers and Educators Assistance Program) and 74 O.S. 2021 §§3200.1-3200.2 (Health Care Workforce Resources Act). This bill eliminates the legal framework for these specific programs, which previously provided assistance to health care workers and educators. The repeal takes effect on November 1, 2026, and directly affects the administrative structure and operations of those programs. No new provisions or funding are created; the bill solely removes the existing laws.
HB 3767 adds specific synthetic drugs and substances to Oklahoma's Schedule I and IV of controlled dangerous substances under state law. It directly affects anyone possessing, distributing, or using the newly listed compounds, including various fentanyl analogs (like para-fluorofentanyl), synthetic hallucinogens (like psilocybin and salvia), and other novel psychoactive substances. The bill amends Oklahoma's Controlled Dangerous Substances Act by expanding the official lists in Schedule I (substances with no medical use and high abuse potential) and Schedule IV (substances with accepted medical use but potential for abuse). This creates new legal prohibitions for these substances without requiring additional medical or legal exceptions.
SB 1567 modifies Oklahoma's rules for Advanced Practice Registered Nurses (APRNs) by allowing supervising physicians to charge reasonable fees for oversight services, requiring these fees to be disclosed in written agreements and based on fair market value. The bill prohibits the Oklahoma Board of Nursing from imposing fees for maintaining supervision agreements or related administrative tasks. It also mandates that supervision agreements include specific details like fee structures, scope of practice, emergency plans, and alternate physician designations. This directly affects APRNs who rely on physician supervision and supervising physicians, streamlining oversight requirements while ensuring transparency in fee arrangements.
HB 1168 makes it a felony to knowingly deliver or possess abortion-inducing drugs (like misoprostol or methotrexate) with the intent of causing an abortion, punishable by up to $100,000 in fines or 10 years in prison. It directly affects individuals who provide such drugs for non-exceptional purposes, including off-label use for abortion. Key exceptions include pharmacists, manufacturers, and distributors acting within lawful medical practices, as well as preventive contraception used as directed by manufacturers. The law does not restrict treatment for ectopic pregnancies, miscarriages, or medical uses of drugs like chemotherapy.
HB 3143 extends Oklahoma's moratorium on new medical marijuana business licenses (dispensaries, processors, growers) from August 1, 2026, to August 1, 2028. It requires existing license holders to get written approval from the Oklahoma Medical Marijuana Authority before transferring ownership, including submitting documentation to the Oklahoma State Bureau of Narcotics. Transfers must follow a 15-business-day timeline for license and registration changes, and applicants cannot submit transfer requests if disciplinary actions are pending. The bill also mandates that businesses provide a full inventory of all medical marijuana products during ownership changes and prohibits transfers without approval, with a 30-day window for pending applications to comply with new rules.
SB 1625 requires the Oklahoma Insurance Department to conduct a detailed impact analysis for any new law that would mandate changes to health insurance coverage (like adding specific treatments or requiring prior authorization). The analysis must evaluate social impact (public health benefits and affected populations), medical effectiveness (scientific evidence), and financial effects (premium changes and market stability) before such bills can be voted on. The department may hire outside experts for this analysis and must make the reports publicly available online. The bill takes effect November 1, 2026.
SB 1352 modifies Oklahoma's medical marijuana licensing rules by requiring municipalities to provide specific documentation before blocking license renewals or transfers for dispensaries located too close to schools. It mandates that local governments submit a resolution proving a school was "openly in existence" (with visible signage) before the dispensary opened, plus verified distance measurements using a standardized method. This affects existing medical marijuana businesses seeking renewal or transfer of retail dispensary licenses. The bill aims to prevent automatic renewal of dispensaries near schools without proper municipal review, while requiring certificate of occupancy compliance for facility operations.
SB 207 establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to address the needs of Oklahomans living with rare diseases (defined as conditions affecting fewer than 200,000 people nationally). The Council, composed of 13 diverse members including patients, caregivers, healthcare providers, researchers, and industry representatives, will conduct public hearings, develop policy recommendations, and create emergency care protocols to improve access to specialists, diagnostics, and equitable treatment. The bill also modifies Oklahoma’s newborn screening program to require an educational initiative for treatable genetic disorders, aiming to prevent intellectual disabilities and reduce infant mortality through early intervention. This legislation directly affects rare disease patients, their families, healthcare providers, and state agencies responsible for public health programs in Oklahoma.
HB 2298 allows qualified Advanced Practice Registered Nurses (APRNs) in Oklahoma - such as nurse practitioners and nurse-midwives - to prescribe medications independently after meeting specific requirements. To qualify, APRNs must complete 6,240 supervised clinical hours, hold a valid license, and carry $1 million in malpractice insurance per incident. The bill also sets rules for APRN advertising (requiring clear disclosure of their role and scope) and defines supervision requirements for those not yet eligible for independent prescribing. It modifies Oklahoma’s Nursing Practice Act, Pharmacy Act, and Controlled Substances Act to implement these changes.
